Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.
2.

Boosting endogenous neuroprotection in multiple sclerosis: the ASsociation of Inosine and Interferon beta in relapsing- remitting Multiple Sclerosis (ASIIMS) trial.

Gonsette RE, Sindic C, D'hooghe MB, De Deyn PP, Medaer R, Michotte A, Seeldrayers P, Guillaume D; ASIIMS study group.

Mult Scler. 2010 Apr;16(4):455-62. doi: 10.1177/1352458509360547. Epub 2010 Mar 3.

PMID:
20200198
3.

The treatment of multiple sclerosis with inosine.

Markowitz CE, Spitsin S, Zimmerman V, Jacobs D, Udupa JK, Hooper DC, Koprowski H.

J Altern Complement Med. 2009 Jun;15(6):619-25. doi: 10.1089/acm.2008.0513.

4.
5.

Serum uric acid level in patients with relapsing-remitting multiple sclerosis.

Ashtari F, Bahar M, Aghaei M, Zahed A.

J Clin Neurosci. 2013 May;20(5):676-8. doi: 10.1016/j.jocn.2012.05.054. Epub 2013 Mar 22.

PMID:
23528410
6.

Inactivation of peroxynitrite in multiple sclerosis patients after oral administration of inosine may suggest possible approaches to therapy of the disease.

Spitsin S, Hooper DC, Leist T, Streletz LJ, Mikheeva T, Koprowskil H.

Mult Scler. 2001 Oct;7(5):313-9.

PMID:
11724447
7.

Serum uric acid and multiple sclerosis.

Rentzos M, Nikolaou C, Anagnostouli M, Rombos A, Tsakanikas K, Economou M, Dimitrakopoulos A, Karouli M, Vassilopoulos D.

Clin Neurol Neurosurg. 2006 Sep;108(6):527-31. Epub 2005 Oct 3.

PMID:
16202511
8.
9.

[Clinical assessment of the course of relapsing-remitting multiple sclerosis in patients treated with interferon beta].

Pokryszko-Dragan A, Bilińska M, Gruszka E, Dubik-Jezierzańska M.

Pol Merkur Lekarski. 2005 Nov;19(113):654-8. Polish.

PMID:
16498805
10.

Modulation of serum uric acid levels by inosine in patients with multiple sclerosis does not affect blood pressure.

Spitsin S, Markowitz CE, Zimmerman V, Koprowski H, Hooper DC.

J Hum Hypertens. 2010 May;24(5):359-62. doi: 10.1038/jhh.2009.83. Epub 2009 Oct 29.

PMID:
19865105
11.

Effects of IV methylprednisolone on brain atrophy in relapsing-remitting MS.

Zivadinov R, Rudick RA, De Masi R, Nasuelli D, Ukmar M, Pozzi-Mucelli RS, Grop A, Cazzato G, Zorzon M.

Neurology. 2001 Oct 9;57(7):1239-47.

PMID:
11591843
12.

Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial.

Confavreux C, O'Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, Wolinsky JS, Bagulho T, Delhay JL, Dukovic D, Truffinet P, Kappos L; TOWER Trial Group.

Lancet Neurol. 2014 Mar;13(3):247-56. doi: 10.1016/S1474-4422(13)70308-9. Epub 2014 Jan 23.

PMID:
24461574
13.

Severe disability in patients with relapsing-remitting multiple sclerosis is associated with profound changes in the regulation of leptin secretion.

Rotondi M, Batocchi AP, Coperchini F, Caggiula M, Zerbini F, Sideri R, Leporati P, Nociti V, Frisullo G, Mirabella M, Magri F, Oliviero A, Chiovato L.

Neuroimmunomodulation. 2013;20(6):341-7. doi: 10.1159/000353567. Epub 2013 Aug 30.

PMID:
24008588
14.

Oral versus intravenous steroids for treatment of relapses in multiple sclerosis.

Burton JM, O'Connor PW, Hohol M, Beyene J.

Cochrane Database Syst Rev. 2012 Dec 12;12:CD006921. doi: 10.1002/14651858.CD006921.pub3. Review.

PMID:
23235634
15.

Associated Inosine to interferon: results of a clinical trial in multiple sclerosis.

Muñoz García D, Midaglia L, Martinez Vilela J, Marín Sánchez M, López González FJ, Arias Gómez M, Dapena Bolaño D, Iglesias Castañón A, Alonso Alonso M, Romero López J.

Acta Neurol Scand. 2015 Jun;131(6):405-10. doi: 10.1111/ane.12333. Epub 2014 Oct 14.

PMID:
25313094
16.

Uric acid levels in sera from patients with multiple sclerosis.

Drulović J, Dujmović I, Stojsavljević N, Mesaros S, Andjelković S, Miljković D, Perić V, Dragutinović G, Marinković J, Lević Z, Mostarica Stojković M.

J Neurol. 2001 Feb;248(2):121-6.

PMID:
11284129
17.
18.

Reduction of disease activity and disability with high-dose cyclophosphamide in patients with aggressive multiple sclerosis.

Krishnan C, Kaplin AI, Brodsky RA, Drachman DB, Jones RJ, Pham DL, Richert ND, Pardo CA, Yousem DM, Hammond E, Quigg M, Trecker C, McArthur JC, Nath A, Greenberg BM, Calabresi PA, Kerr DA.

Arch Neurol. 2008 Aug;65(8):1044-51. doi: 10.1001/archneurol.65.8.noc80042. Epub 2008 Jun 9.

19.

[Evaluation of the long term effect of mitoxantrone on neurological disability in patients with active multiple sclerosis].

Mesaros S, Stojsavljević N, Dujmović I, Mandić E, Drulović J.

Srp Arh Celok Lek. 2004 Jul-Aug;132(7-8):209-13. Serbian.

20.

Serum uric acid levels in patients with multiple sclerosis: a meta-analysis.

Liu B, Shen Y, Xiao K, Tang Y, Cen L, Wei J.

Neurol Res. 2012 Mar;34(2):163-71. doi: 10.1179/1743132811Y.0000000074. Epub 2012 Jan 31.

PMID:
22333889

Supplemental Content

Support Center